India should resist pressure from the European Union to accept, as part of a free trade agreement, harmful provisions that will have a major negative impact on the availability of affordable medicines, the international medical humanitarian organisation Medecins Sans Frontieres (MSF) last week.
The MSF last year launched a campaign demanding “Europe! HANDS OFF our medicine,” which it renewed while the trade talks were taking place in Brussels, Belgium (The Pharma Letter November 9, 2010).
As discussions on the sensitive intellectual property chapter in the free trade agreement resume, reports now indicate the Indian Prime Minister’s Office (PMO) may be ready to concede to European demands, imposing severe limitations on the ability of Indian generic manufacturers to produce affordable medicines, says MSF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze